Leadership changes at Teva
pharmafile | November 8, 2012 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Levin, Teva
Teva Pharmaceutical has announced some management changes to its executive leadership team.
Allan Oberman, senior vice president of North America Generic Pharmaceuticals has been appointed president and chief executive of Teva Americas Generics as part of an orderly management succession.
In his new role Oberman will report directly to Jeremy Levin, Teva’s president and chief executive, and have continued responsibility for North America Generics as well as overall management of Teva’s Latin American businesses.
The Company also announced the appointment of Jill DeSimone to the newly created position of senior vice president and general manager of Teva Global Women’s Health where she will oversee all aspects of this franchise.
“These changes are part of our ongoing process to build a premier leadership team and reshape Teva,” said Levin. “Allan brings extensive experience in global generics to the Company’s Americas teams. Jill brings a great track record and many years of experience in building franchises in speciality medicine. We look forward to her contributions in leading our Women’s Health business.”
Teva also announced today that as part of the succession, William Marth (pictured) will step down as president and chief executive of Teva Americas effective immediately and retire at the end of 2013. Marth will serve as a senior advisor to Levin until his retirement.
“We greatly appreciate the contributions that Bill has made to Teva over the years, most recently leading the Teva businesses in the Americas. During this time, the Company experienced significant growth. We thank him for his tremendous service to the Company and look forward to working with him over the next year in his new capacity as a core advisor.” said Levin.
Related Content
Teva’s Ajovy significantly reduces migraine in children and adolescents
Teva’s Ajovy (fremanezumab) has demonstrated significant reduction in monthly migraine and headache days in children …
Teva announces positive results from trial of AJOVY for migraine
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …
Sanofi and Teva partner for development of inflammatory bowel disease treatment
Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation …
